Flex Pharma Demonstrates Efficacy Of Synthesized Single And Combination Agents In Reducing Human Muscle Cramps

BOSTON--(BUSINESS WIRE)--Click to Tweet this News

“We are excited to be on the forefront of investigating chemical neuro stimulation as a novel and perhaps generally applicable method to treat disorders of cramping and spasms stemming from alpha motor neuron hyperexcitability.”

Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions, announced today that it will present data demonstrating the efficacy of purified, GMP-synthesized single molecules, as well as combinations of two individual molecules, of TRPA1 and TRPV1 agonists, in significantly reducing human muscle cramp intensity in its electrically induced cramp model at the European Committee for Treatment and Research of Multiple Sclerosis (ECTRIMS) in Barcelona, Spain at 9:45am ET on October 8, 2015.

The abstract titled, “TRPV1 and TRPA1 activators reduce muscle cramping: Potential new treatment for MS symptoms,” will be presented by neurologist and Flex Pharma Chief Medical Officer, Dr. Tom Wessel, who served as the medical lead for three products approved in United States: Razadyne®, Lunesta® and Ampyra®. “By testing the most potent TRPA1 and TRPV1 agonists and demonstrating enhanced efficacy with purified single agent and doublet combinations compared to the original proprietary formulation, we have made significant progress in our product development efforts,” said Dr. Wessel. Utilizing the established electrically induced model in normal healthy volunteers (n=9), the purified single molecules, as well as combinations of two individual molecules, of GMP-synthesized TRPA1 and TRPV1 agonists, significantly reduced cramp intensity relative to vehicle control (p<0.01) and compared to the original proprietary formulation of extract mixture (p<0.05).

Nobel laureate and Flex Pharma Scientific Co-Founder and Scientific Advisory Board Co-Chair, Dr. Rod MacKinnon noted, “We are excited to be on the forefront of investigating chemical neuro stimulation as a novel and perhaps generally applicable method to treat disorders of cramping and spasms stemming from alpha motor neuron hyperexcitability.”

About Flex Pharma

Flex Pharma, Inc. is a biotechnology company that is developing innovative and proprietary treatments for exercise-associated muscle cramps, nocturnal leg cramps, and spasms associated with severe neuromuscular conditions. In three randomized, blinded, placebo-controlled, cross-over studies, Flex Pharma’s proprietary treatment has shown a statistically significant reduction in the intensity of muscle cramps in healthy normal volunteers.

Flex Pharma was founded by National Academy of Sciences members Rod MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized leaders in the fields of ion channels and neurobiology, along with Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.

Individuals can follow the Company on Twitter (@flexpharma) and the Company’s website (http://ir.flex-pharma.com/) to see the latest progress of the Company’s pre-launch activities for its consumer product to prevent and treat exercise-associated muscle cramps.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our expectations regarding potential drug and consumer product candidates, the design and timing of ongoing and anticipated clinical studies and our drug development progress. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation: the status, timing, costs, results and interpretation of our clinical studies; the uncertainties inherent in conducting clinical studies; results from our ongoing and planned preclinical development; expectations of our ability to make regulatory filings and obtain and maintain regulatory approvals; results of early clinical studies as indicative of the results of future trials; the inherent uncertainties associated with intellectual property; and other factors discussed in greater detail under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2014 and subsequent filings with the Securities and Exchange Commission (SEC). You are encouraged to read our filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. Any forward-looking statements that we make in this press release speak only as of the date of this press release. We assume no obligation to update our forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.